Placebo response rates in randomized controlled trials for perianal Crohn's disease: A systematic review and meta-analysis.
Fiche publication
Date publication
octobre 2022
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Sharma T, Ma C, Sedano R, Hanzel J, McDonald C, Hogan M, Kochhar GS, Narula N, Peyrin-Biroulet L, Danese S, MacDonald JK, Jairath V
Lien Pubmed
Résumé
Perianal fistulizing disease is a common complication of Crohn's disease (CD), for which new therapies are urgently needed. To assist design of clinical trials for novel therapeutics, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to quantify placebo rates and identify factors influencing them in perianal CD.
Mots clés
Clinical trials, Peri-anal Crohn’s Disease, Placebo
Référence
J Crohns Colitis. 2022 10 22;: